Insulin Lispro
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Insulin Lispro: From Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin lispro is a rapid-acting insulin analogue, originally used to control blood glucose in type 1 and type 2 diabetes mellitus and to treat diabetic ketoacidosis. The TxGNN model predicts it may be effective for autoimmune oophoritis, but no clinical trials and no publications currently support this prediction. The prediction is best regarded as a model-derived hypothesis rather than a therapeutic lead.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 1 and type 2 diabetes mellitus, diabetic ketoacidosis (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Autoimmune oophoritis |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this report. Based on general knowledge, insulin lispro is a rapid-acting insulin analogue that binds the insulin receptor to regulate glucose metabolism. Its efficacy in diabetes is well established.
Autoimmune oophoritis is an immune-mediated ovarian disorder. It often occurs within autoimmune polyendocrine syndromes, which can include type 1 diabetes. No direct mechanistic link between insulin lispro and this condition has been established. The high score most likely reflects proximity in the knowledge graph through shared autoimmune endocrine comorbidity, not a therapeutic effect.
Other predictions (ranks 2–10) were also reviewed. None has clinical trial support:
| Rank | Predicted Indication | Score | Assessment |
|---|---|---|---|
| 2 | Thiamine-responsive dysfunction syndrome | 99.37% | Insulin would treat only the accompanying diabetes, not the underlying defect |
| 3 | Focal stiff limb syndrome | 99.36% | Link through shared anti-GAD65 autoimmunity; no action on the neuromuscular pathology |
| 4 | Classic stiff person syndrome | 99.36% | Same as above; insulin would treat only comorbid diabetes |
| 5 | Opsismodysplasia | 99.34% | Biologically plausible link via INPPL1/SHIP2 in insulin signalling; direction of effect unproven |
| 6 | Drug-induced localized lipodystrophy | 99.09% | Insulin is a known cause, not a treatment; use would be inappropriate |
| 7 | Pancreatic agenesis | 99.09% | Insulin replacement is physiologically rational; the only linked paper is an indirect review (L4) |
| 8 | Centrifugal lipodystrophy | 99.04% | No established mechanism |
| 9 | Pressure-induced localized lipoatrophy | 99.03% | Likely a knowledge-graph artefact; injection-site lipoatrophy is a known insulin adverse effect |
| 10 | Idiopathic localized lipodystrophy | 98.97% | Association more likely adverse than therapeutic |
Pancreatic agenesis is the most biologically coherent of these, because insulin replacement for an insulin-deficient state is consistent with the drug's existing use. It would be an extension of the current indication rather than true repurposing.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature is available for the top-ranked prediction (autoimmune oophoritis). One publication is linked to the rank 7 prediction (pancreatic agenesis):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12150359 | 2002 | Review | J Am Pharm Assoc | General review of insulin therapy in type 2 diabetes and practical aspects of starting it; indirect evidence only |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13719P | HUMALOG KWIKPEN 100 units/ml | Injection | Not stated in the data compiled |
| SIN11227P | HUMALOG MIX 25 Suspension for Injection 100 iu/ml | Injection | Not stated in the data compiled |
| SIN11171P | HUMALOG MIX25 KWIKPEN 100 units/ml | Injection | Not stated in the data compiled |
All three registrations are valid single-ingredient products, available as injectables only.
Safety Considerations
Drug Interactions: The interaction screening returned 100 records. Most of the 20 listed were Moderate, with a few Minor. The main ones are:
- Glucose-lowering agents (additive hypoglycaemia risk or altered glycaemic control): metformin, alogliptin, albiglutide, alpelisib
- Sympathomimetics and beta-agonists (may reduce glucose-lowering effect): epinephrine, phenylephrine, pseudoephedrine, salbutamol, formoterol
- Beta-blocker: acebutolol (may mask hypoglycaemia symptoms)
- Hormonal agents and corticosteroids: estradiol, ethinylestradiol, levonorgestrel, hydrocortisone (Minor for topical forms)
- Others: acetazolamide, hydrochlorothiazide, doxycycline, ethanol
Injection-site lipodystrophy and lipoatrophy are known adverse effects of insulin therapy. This matters directly for the predicted lipodystrophy indications (ranks 6, 8, 9 and 10).
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, autoimmune oophoritis, has no clinical trials or literature, no mechanistic link, and a score that likely reflects comorbidity proximity in the knowledge graph. Evidence is L5 (model prediction only).
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, and approved indication text for the three Singapore licences
- Mechanism of action data from DrugBank
- A targeted literature search on insulin and autoimmune ovarian disease
- Consideration of pancreatic agenesis (L4) as a separate research question, given the physiological rationale for insulin replacement
- Exclusion of the lipodystrophy-related predictions, since insulin can cause these conditions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.